Health AI Central
Share:
Peer-Reviewed Publication
Toxicol Rep2026;16102179.June 1, 2026Journal Article

Can in silico models predict drug-induced cardiac risk in vulnerable populations?

Paula Dominguez-Gomez1,2, Pablo Gonzalez-Martin1,2, Laura Baldo-Canut1, Eva Casoni1, Ani Amar1, Jose M Pozo1, Constantine Butakoff1, Mariano Vazquez1,3, Jazmin Aguado-Sierra1
1Elem Biotech, Pier 07, Via Laietana, 26, Barcelona, 08003, Spain.
2University Pompeu Fabra, Carrer de Tànger, 122-140, Barcelona, 08018, Spain.
3Barcelona Supercomputing Center, Plaça d'Eusebi Güell, 1-3, Barcelona, 08034, Spain.
PubMed PMC DOI PDF

Abstract

This study evaluates virtual cardiac populations for preclinical assessment of drug-induced QT interval prolongation and arrhythmic risk. Traditional predictions often rely on small, healthy cohorts, excluding vulnerable populations. Using computational models of realistic heart anatomies and electrophysiology, we generated a virtual cohort of 512 subjects across healthy and diseased hearts (heart…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.